Beijing Jingdu Children's Hospital
One of China's largest private pediatric tertiary hospitals, JCI accredited, offering stem cell transplantation and CAR-T cell therapy for childhood blood cancers, genetic diagnostics, and 24 clinical departments across 300 beds in a child-friendly healing environment.
About Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital is one of the largest private pediatric tertiary hospitals in China, located in Changping District, Beijing. Founded in 2013, the hospital has grown into a nationally recognised centre offering comprehensive care for complex childhood diseases across 24 clinical departments, 300 beds, and over 600,000 annual outpatient visits. The hospital holds JCI accreditation, recognising its compliance with international patient safety and quality standards. It is designed as a child-friendly healing environment with bright, welcoming interiors, play areas, and family-centred spaces to reduce anxiety and support wellbeing during treatment.
The hospital's Pediatric Hematology and Oncology department is its most internationally relevant specialty for cancer patients, offering diagnosis and treatment of childhood blood cancers including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), lymphoma, and other haematologic malignancies. Advanced treatment capabilities include allogeneic and autologous hematopoietic stem cell transplantation (HSCT), CAR-T cell therapy for relapsed or refractory paediatric haematologic malignancies, molecular profiling and genetic diagnostics for precision treatment decisions, and laminar flow transplant units for post-transplant isolation. Dr. Sun Yuan specialises in paediatric haematology and oncology including stem cell transplantation in children.
CancerFax works with Beijing Jingdu Children's Hospital to help international families access its specialist paediatric oncology programmes. For childhood leukaemia, lymphoma, and other haematologic malignancies where HSCT or CAR-T is indicated, CancerFax provides pre-screening, medical record review and translation, eligibility assessment, Chinese visa documentation, and on-ground coordination — at no cost to the family. We compare Jingdu against other Chinese paediatric oncology centres including Nanfang-Chunfu in Dongguan and Shenzhen Children's Hospital before any travel commitment.
| Hospital at a Glance | |
|---|---|
| Country | China |
| City | Beijing (Changping District) |
| Founded | 2013 |
| Hospital Type | Private Pediatric Tertiary Hospital |
| Accreditation | JCI (⚠ VERIFY current validity period) |
| Beds | 300 beds |
| Annual Outpatients | 600,000+ |
| Key Oncology Programmes | Pediatric Hematology/Oncology · HSCT (autologous and allogeneic) · CAR-T Cell Therapy · Genetic Diagnostics · Molecular Profiling |
Why Families Choose Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital combines JCI-accredited paediatric oncology expertise with HSCT and CAR-T capability for children, genetic diagnostics, and a child-friendly healing environment — in a private hospital setting that is accessible for international families travelling to Beijing.
Cancer Specialties and Clinical Departments
Beijing Jingdu Children's Hospital's oncology focus is paediatric haematology and oncology, with HSCT and CAR-T capabilities for childhood blood cancers, alongside genetic diagnostics and multi-disciplinary support across 24 clinical departments.
Advanced Treatment Capabilities
Key Specialists at Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital's paediatric oncology leadership includes specialists in haematologic malignancies and stem cell transplantation in children. Dr. Sun Yuan specialises in paediatric haematology and oncology including HSCT. The full clinical team covers 24 departments across paediatric medicine, surgery, and subspecialties. Specific consultant names and titles for the oncology team should be confirmed from the hospital's official website (jdetyy.com) before any travel commitment.
CancerFax matches families with the appropriate Jingdu paediatric oncology specialist based on the child's diagnosis, molecular subtype, prior treatment history, and current clinical requirements. We confirm in advance which consultant will be assigned to the case, and we compare Jingdu openly against Nanfang-Chunfu in Dongguan and Shenzhen Children's Hospital before any travel decision.
⚠ VERIFY: Full oncology team names and titles from jdetyy.com before publishing. CancerFax can confirm the treating consultant for each paediatric case.
Clinical Infrastructure at Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital operates 300 beds across 24 clinical departments in a purpose-built child-friendly private tertiary facility in Changping District, Beijing, with laminar flow transplant units, advanced genetics laboratory, and comprehensive paediatric imaging.
- Laminar flow transplant units for HSCT and post-transplant isolation
- CAR-T cell therapy for eligible paediatric relapsed/refractory haematologic malignancies
- Hematology laboratory with flow cytometry, cytogenetics, and MRD monitoring
- Comprehensive genetic and molecular testing laboratory for paediatric oncology
- Targeted therapy selection based on molecular profiling and genomic diagnostics
- Clinical decision support for CAR-T eligibility and HSCT donor matching
- Dedicated paediatric ICU and NICU with advanced life-support for critically ill children
- 24-hour paediatric emergency department
- Advanced imaging: MRI, CT, ultrasound; minimally invasive surgical systems
International Patient Support at Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital has a dedicated international patient department with translation and interpretation services, visa invitation letters, airport pickup, and accommodation guidance for families travelling to Beijing for paediatric oncology care.
What to Prepare Before Traveling
- arrow_rightShare the child's complete haematology and oncology records — bone marrow biopsy and aspirate findings, flow cytometry and cytogenetics, recent imaging (CT, PET-CT, MRI), molecular and MRD data, prior chemotherapy, CAR-T or transplant treatment summaries — with CancerFax at least two to three weeks before the planned consultation at Jingdu.
- arrow_rightApply for an appropriate Chinese visa (M for medical or L for tourist) at your nearest Chinese consulate. Beijing Jingdu Children's Hospital can issue an official invitation letter for the patient and accompanying family members.
- arrow_rightPlan travel via Beijing Capital International Airport (PEK) or Beijing Daxing International Airport (PKX). Allow at least four to eight weeks for CAR-T treatment and monitoring, or three to six months for allogeneic HSCT including conditioning, transplant, and post-transplant recovery.
Beijing Jingdu Children's Hospital can be contacted via jdetyy.com. CancerFax coordinates all submissions, translation, visa and travel arrangements on the family's behalf, and compares Jingdu with other Chinese paediatric oncology centres at no cost to the family.
Patient Facilities at Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital is purpose-designed as a child-friendly private tertiary facility with family-centred spaces, play areas, laminar flow transplant units, on-site pharmacy, and psychological support services across its 300-bed campus.
Families accompanying children to Beijing Jingdu Children's Hospital can access accommodation near the Changping District campus. CancerFax assists with extended-stay planning for families during HSCT (typically 3-6 months) or CAR-T therapy (typically 4-8 weeks including leukapheresis, manufacturing, infusion and monitoring).
How to Reach Beijing Jingdu Children's Hospital
Beijing Jingdu Children's Hospital is located in Changping District, Beijing, accessible from both Beijing Capital International Airport and Beijing Daxing International Airport.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Beijing Jingdu Children's Hospital — Patient Questions Answered
The hospital treats a wide range of childhood cancers including leukaemia (ALL, AML), lymphoma, neuroblastoma, Wilms tumour, brain tumours, bone tumours (osteosarcoma, Ewing sarcoma), retinoblastoma, and soft tissue sarcomas, using advanced therapies including stem cell transplantation and CAR-T cell therapy. CancerFax can confirm whether your child's specific diagnosis is appropriate for Jingdu versus other Chinese paediatric oncology centres before any travel commitment.
CAR-T cell therapy is available for paediatric patients with relapsed or refractory haematologic malignancies. Specific CAR-T products, eligible diagnoses, and current enrolment criteria should be confirmed with the hospital before travel. CancerFax facilitates this eligibility assessment and compares Jingdu's CAR-T programme with Nanfang-Chunfu and Shenzhen Children's Hospital — both also strong paediatric haematology centres in China with HSCT and CAR-T programmes.
International families can connect through CancerFax for end-to-end support including medical record review and translation, eligibility assessment, Chinese visa documentation, airport pickup, accommodation guidance, and on-ground coordination during the treatment journey — at no cost to the family. CancerFax also provides honest comparison with other Chinese paediatric oncology options before any decision.
Yes. Both autologous and allogeneic hematopoietic stem cell transplantation (HSCT) are available for eligible paediatric patients with blood cancers and other haematologic conditions. HSCT is performed in laminar flow transplant units with appropriate infection control protocols for paediatric patients.
Beijing Jingdu Children's Hospital is one of China's largest private paediatric tertiary hospitals with JCI accreditation and a strong paediatric haematology/oncology focus including HSCT and CAR-T. CancerFax compares Jingdu alongside Nanfang-Chunfu Children's Institute of Haematology and Oncology in Dongguan and Shenzhen Children's Hospital — all three are relevant paediatric oncology options in China for HSCT and CAR-T. The choice depends on the child's specific diagnosis, CAR-T construct availability, donor matching status, and family logistics. CancerFax evaluates all three before recommending a path.
Send Your Child's Medical Reports to Beijing Jingdu Children's Hospital via CancerFax
CancerFax reviews your child's records, assesses HSCT or CAR-T eligibility at Beijing Jingdu Children's Hospital, compares with Nanfang-Chunfu and Shenzhen Children's Hospital, and coordinates your consultation in Beijing at no cost, with no obligation, and with full medical confidentiality.